Product logins

Find logins to all Clarivate products below.


Alison Isherwood

Director, Epidemiology & Real-World Evidence

Dr. Alison Isherwood is a Director in Clarivate’s Commercial Strategy Consulting Epidemiology & Real-World Evidence team.

Alison has over 16 years of consultancy experience in healthcare and life sciences consultancy, specializing in epidemiological and RWE-based insights and solutions. Her role is to use secondary data and US and European real-world data (RWD) to provide strategic epidemiological insights for business stakeholders in commercial and HEOR roles.

Alison held the roles of Research Scientist at Evidera designing and executing RWE-based outcomes research studies. Prior to this, she the Director of Epidemiology for DRG’s Syndicated Epidemiology team where she gained considerable experience in patient population sizing with incidence and prevalence risk-based forecast modelling across a portfolio of 200 diseases in over 40 countries.

She holds a Doctoral degree from the University of Reading (UK), and an MSc in Epidemiology, an MRes in Life Sciences and a BSc in Medical Microbiology all from the University of Edinburgh.


arrow_forward
Get in touch with Alison

Latest news

News August 6, 2026
Clarivate Scales Agentic AI Across Cortellis to Advance Drug Development

Expanded capabilities across Cortellis portfolio help life sciences organizations turn trusted intelligence into action and accelerate decision making across the research and development lifecycle London, U.K. — August 6, 2026— Clarivate…

News August 5, 2026
Clarivate Companies to Watch Report Spotlights Seven Innovators Shaping the Next Generation of Obesity Therapies

New report examines novel mechanisms and emerging approaches advancing obesity treatment beyond today’s GLP-1 therapies London, U.K., August 5, 2026 — Clarivate Plc (NYSE:CLVT), a leading global provider of transformative…

News July 29, 2026
Clarivate Appoints Michael Easton as Chief Financial Officer

Experienced Clarivate leader brings more than 25 years of financial and operational expertise ​LONDON, July 29, 2026: Clarivate Plc (NYSE: CLVT) (“Clarivate” or the “Company”), a leading global provider of transformative intelligence, today…

Related resources

Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval
Blog June 24, 2026
Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval
ADC Biopharma Biotech Bispecific antibodies BsAb Clinical trials Development Oncology Pharma R&D Regulatory Research
Using AI-powered translational safety intelligence to anticipate drug safety issues earlier Using AI-powered translational safety intelligence to anticipate drug safety issues earlier
Blog June 22, 2026
Using AI-powered translational safety intelligence to anticipate drug safety issues earlier
Biopharma Biotech Clinical trials CMC Development R&D Real-World Data Regulatory Research Safety
Three uncomfortable truths about cell and gene therapy in regulatory affairs Three uncomfortable truths about cell and gene therapy in regulatory affairs
Blog May 28, 2026
Three uncomfortable truths about cell and gene therapy in regulatory affairs
Consulting Resource Center Regulatory
How the Inflation Reduction Act could impact access to more convenient therapeutics How the Inflation Reduction Act could impact access to more convenient therapeutics
Blog February 17, 2026
How the Inflation Reduction Act could impact access to more convenient therapeutics
Biopharma Biotech Commercialization Consulting Resource Center FDA HMO Insurance Launch Managed care Market Access North America Payer Pharma pricing Route of administration U.S.